Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
81.77
-0.06 (-0.07%)
At close: Dec 5, 2025, 4:00 PM EST
81.76
-0.01 (-0.01%)
After-hours: Dec 5, 2025, 6:05 PM EST
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Tarsus Pharmaceuticals stock ranges from a low of $51 to a high of $100. The average analyst price target of $73.63 forecasts a -9.95% decrease in the stock price over the next year.
Price Target: $73.63 (-9.95%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tarsus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Initiates $100 | Buy | Initiates | $100 | +22.29% | Nov 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $84 → $87 | Strong Buy | Maintains | $84 → $87 | +6.40% | Nov 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $72 → $88 | Strong Buy | Maintains | $72 → $88 | +7.62% | Oct 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $72 | Strong Buy | Initiates | $72 | -11.95% | May 27, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $46 → $51 | Hold | Maintains | $46 → $51 | -37.63% | May 5, 2025 |
Financial Forecast
Revenue This Year
452.34M
from 182.95M
Increased by 147.24%
Revenue Next Year
692.58M
from 452.34M
Increased by 53.11%
EPS This Year
-1.53
from -3.07
EPS Next Year
1.82
from -1.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 467.5M | 815.5M | ||||
| Avg | 452.3M | 692.6M | ||||
| Low | 433.6M | 592.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 155.5% | 80.3% | ||||
| Avg | 147.2% | 53.1% | ||||
| Low | 137.0% | 30.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.38 | 3.37 | ||||
| Avg | -1.53 | 1.82 | ||||
| Low | -2.05 | 0.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.